Methotrexate-associated lymphoproliferative disorder

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Methotrexate-associated lymphproliferative disorder (MTX-LPD) is a rare but critical complication developing in patients treated with methotrexate. Now that methotrexate is an anchor drug in the management of rheumatoid arthritis and become commonly used, MTX-LPD cases have increased. Many things has been unclear such as incidence, demographic characters, and risk factors. However, as the researches increased, several interesting topics has been demonstrated like associations with Epsteiin-Barr virus and with cell-mediated immunity. This report reviews newly the latest findings and future challenges on MTX-LPD.

Original languageEnglish
Pages (from-to)174-178
Number of pages5
JournalJapanese Journal of Clinical Immunology
Volume40
Issue number3
DOIs
Publication statusPublished - 2017

Fingerprint

Lymphoproliferative Disorders
Methotrexate
Cellular Immunity
Rheumatoid Arthritis
Demography
Viruses
Incidence
Research
Pharmaceutical Preparations

Keywords

  • Lymphoproliferative disorder
  • Methotrexate
  • Rheumatoid arthritis

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Methotrexate-associated lymphoproliferative disorder. / Kaneko, Yuko.

In: Japanese Journal of Clinical Immunology, Vol. 40, No. 3, 2017, p. 174-178.

Research output: Contribution to journalArticle

@article{4f3f4a75e6a145da9f0c37d024f4e5c0,
title = "Methotrexate-associated lymphoproliferative disorder",
abstract = "Methotrexate-associated lymphproliferative disorder (MTX-LPD) is a rare but critical complication developing in patients treated with methotrexate. Now that methotrexate is an anchor drug in the management of rheumatoid arthritis and become commonly used, MTX-LPD cases have increased. Many things has been unclear such as incidence, demographic characters, and risk factors. However, as the researches increased, several interesting topics has been demonstrated like associations with Epsteiin-Barr virus and with cell-mediated immunity. This report reviews newly the latest findings and future challenges on MTX-LPD.",
keywords = "Lymphoproliferative disorder, Methotrexate, Rheumatoid arthritis",
author = "Yuko Kaneko",
year = "2017",
doi = "10.2177/jsci.40.174",
language = "English",
volume = "40",
pages = "174--178",
journal = "Immunological Medicine",
issn = "0911-4300",
publisher = "Taylor and Francis Ltd.",
number = "3",

}

TY - JOUR

T1 - Methotrexate-associated lymphoproliferative disorder

AU - Kaneko, Yuko

PY - 2017

Y1 - 2017

N2 - Methotrexate-associated lymphproliferative disorder (MTX-LPD) is a rare but critical complication developing in patients treated with methotrexate. Now that methotrexate is an anchor drug in the management of rheumatoid arthritis and become commonly used, MTX-LPD cases have increased. Many things has been unclear such as incidence, demographic characters, and risk factors. However, as the researches increased, several interesting topics has been demonstrated like associations with Epsteiin-Barr virus and with cell-mediated immunity. This report reviews newly the latest findings and future challenges on MTX-LPD.

AB - Methotrexate-associated lymphproliferative disorder (MTX-LPD) is a rare but critical complication developing in patients treated with methotrexate. Now that methotrexate is an anchor drug in the management of rheumatoid arthritis and become commonly used, MTX-LPD cases have increased. Many things has been unclear such as incidence, demographic characters, and risk factors. However, as the researches increased, several interesting topics has been demonstrated like associations with Epsteiin-Barr virus and with cell-mediated immunity. This report reviews newly the latest findings and future challenges on MTX-LPD.

KW - Lymphoproliferative disorder

KW - Methotrexate

KW - Rheumatoid arthritis

UR - http://www.scopus.com/inward/record.url?scp=85026402854&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85026402854&partnerID=8YFLogxK

U2 - 10.2177/jsci.40.174

DO - 10.2177/jsci.40.174

M3 - Article

VL - 40

SP - 174

EP - 178

JO - Immunological Medicine

JF - Immunological Medicine

SN - 0911-4300

IS - 3

ER -